Presence Of Patient Experience Data Table In FDA Drug Review Summaries ‘Inconsistent’
Executive Summary
RTI Health Solutions researchers assessed US FDA review documents over past two years to gauge use of a tool meant to facilitate agency disclosures about what patient experience information it considered.
You may also be interested in...
FDA Looking To Boost Transparency On How Patient Input Is Used In Drug Reviews
Sponsor concerns about commercial confidential information may be a sticking point in getting patient groups the desired data on when and how the FDA uses patient input in regulatory decision making.
US FDA Should Explain How It Uses Patient Experience Data In Drug Approvals – Report
Review documents do not always reflect whether PED was considered as part of an application, and stakeholders cannot easily determine how such data are used in the agency’s regulatory decision-making, an independent consultant review found.
'Patient Experience Data' Section Added To US FDA Drug Reviews
Genentech's hemophilia A treatment Hemlibra is among first products to include new dedicated section on patient experience data in its review documents as FDA begins implementing 21st Century Cures Act provision.